Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.
Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.
Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.
Deal making in biosimilars dominates a slow start to the year for biopharma M&A.
A correction – as long as it is not too severe – might not be a bad thing for the sector.
But how long can the money keep rolling in?